Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of breast cancer confirmed by laboratory testing, including invasive ductal carcinoma, ductal carcinoma in situ (DCIS), or certain other subtypes (medullary, papillary, mucinous/colloid, or tubular).
- People aged over 50.
- People whose tumour measures less than 2.0cm (or less than 2.5cm if it is pure DCIS).
- People whose breast cancer tests positive for estrogen receptors (more than 10%).
- People whose cancer is suitable for breast-conserving surgery (a lumpectomy), with a clear margin of at least 2mm of healthy tissue around the removed tumour.
- People whose lymph nodes show no signs of cancer spread, based on physical examination — and, if a sentinel node biopsy was performed, the result must also be clear of cancer.
- People with a general health and activity level that falls within a certain acceptable range (confirm with trial site).
Who may not be able to join:
- People whose cancer appears in more than one area of the breast.
- People who have already received chemotherapy before surgery.
- People whose cancer is classified as pure invasive lobular carcinoma.
- People where the surgical cavity cannot be clearly identified on the planning scan taken after the lumpectomy.
- People whose treatment area (as measured on scans) exceeds a certain volume threshold (confirm with trial site).
- People whose surgical cavity sits very close to the surface of the body (within 5mm of the skin's outer contour).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: D. Hunter Boggs, MD, University of Alabama at Birmingham
Phone: (205) 934-5670
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Toxicity levels of 5 fractions SBRT for partial breast irradiation assessed by CTCAE v4.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.